BACKGROUND: This is the first report of long-term (>10 years) safety, tolerability, and survival data on patients with non-small cell lung cancer (NSCLC) who received treatment with gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. METHODS: Patients with advanced NSCLC (N 5 191) who entered the IRESSA Clinical Access Program (ICAP) (June 2011 to January 2013) and had previously obtained a clinical benefit from gefitinib therapy (including patients who had received gefitinib since 2001) were analyzed for adverse events (AEs). A subset of patients (n 5 79) underwent retrospective chart review to capture demographic, safety, and survival data. RESULTS: Seventy-five of 191 patients (39%) remained on long-term gefitinib therapy as of September 2016. Overall, serious AEs (SAEs) were reported in 64 patients (34%), the majority of which were attributed to underlying disease or comorbidities; only 3 patients (1.6%) had SAEs that were considered as possibly gefitinib-related. In the retrospective chart review cohort, 70% of patients were women; 58% were former smokers, and 30% were never-smokers; 56% were diagnosed with adenocarcinoma, and 13% were diagnosed with squamous carcinoma. Although EGFR mutational status was tested in only 17 patients (22%), it was assumed that most tumors were EGFR-mutation-positive. The median duration of gefitinib therapy was 11.1 years (7.8 years before and 3.5 years during ICAP), with 10-year and 15-year survival rates of 86% and 59%, respectively, from the initiation of therapy. CONCLUSIONS: A subset of long-term NSCLC survivors who were receiving gefitinib had an excellent long-term safety profile. Although it is assumed that most of these patients' tumors harbor EGFR mutations, molecular studies of available tumor specimens are planned to uncover the features that predict long-term survival.
INTRODUCTION
Oral tyrosine kinase inhibitors (TKIs) directed at the epidermal growth factor receptor (EGFR) entered clinical trials for patients with non-small cell lung cancer (NSCLC) in the late 1990s. 1, 2 In 2003, gefitinib was the first EGFR TKI to obtain accelerated approval by the US Food and Drug Administration (FDA) based on the notable responses in approximately 10% of unselected patients with advanced NSCLC. 3 Later, in 2004, 3 groups of investigators reported that most of the patients who had dramatic responses to EGFR TKIs had tumors with activating mutations in the EGFR gene. [4] [5] [6] Subsequent randomized trials revealed that EGFR TKIs, including gefitinib, erlotinib, and afatinib, had significantly higher overall response rates (ORRs), longer progression-free survival, improved patient-reported outcomes, and less toxicity compared with chemotherapy as first-line therapy in patients with activating, EGFR-mutation-positive NSCLC. [7] [8] [9] [10] [11] [12] [13] [14] This set into motion new standards in diagnosis and treatment algorithms for NSCLC.
Unfortunately, early randomized trials of gefitinib were designed before the discovery of EGFR mutations and their significance in NSCLC. In June 2005, the FDA revised gefitinib's approval when a randomized trial failed to demonstrate a significant improvement in survival compared with placebo in unselected patients. 15 At that time, patients who already were receiving and benefitting from gefitinib (the majority of whom likely had EGFR-mutation-positive tumors) and patients in a noninvestigational new drug clinical trial approved by an International Review Board (IRB) before June 17, 2005 , were allowed to continue with commercial distribution from a limited number of specialty pharmacies. 3 However, by 2011, AstraZeneca (Wilmington, DE), the drug's manufacturer, voluntarily withdrew gefitinib from the US market. AstraZeneca made provisions for gefitinib to remain available to this limited group of patients in the United States under the IRESSA Clinical Access Program (ICAP) in June 2011. In July of 2015, the FDA approved gefitinib for the first-line treatment of patients with metastatic NSCLC tumors that harbor EGFR mutations (exon 19 deletions or exon 21 [leucine-to-arginine substitution at position 858 (L858R)] substitutions) based on a multicenter, single-arm clinical trial of 106 patients with previously untreated, EGFRmutation-positive, metastatic NSCLC. 16 The ICAP participants constitute a unique subset of patients with cancer in whom long-term use of gefitinib can be studied. This analysis from a subset of the ICAP population describes the long-term safety, tolerability, and effectiveness data from patients with NSCLC who received treatment with gefitinib, some for 10 years' duration or longer.
MATERIALS AND METHODS

Overall IRESSA Clinical Access Program
Population
The ICAP was an IRB-approved, prospective, expanded clinical access program that provided eligible patients with gefitinib treatment and collected patient drug exposure data and information related to serious adverse events (SAEs). No specific efficacy endpoints or other information about participants were collected within the program. Patients were eligible to participate in the ICAP if they provided consent, were aged 18 years, and were currently benefitting from or had benefited from gefitinib treatment or were enrolled in an investigational new drug clinical trial that was IRB approved before June 17, 2005 . Patients who had never previously received gefitinib were not eligible for enrollment in this program. Enrollment was from June 8, 2011 , to January 28, 2013. Patients were supplied gefitinib in unblinded form as 250-mg tablets, which were prescribed according to each patient's regimen at the time of enrollment.
Sponsor safety database analysis
According to ICAP protocol requirements, investigators enrolled in ICAP were responsible for reporting all SAEs observed to the sponsor's Patient Safety Data Entry Site, including study and patient identification. The SAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) into Preferred Terms. All SAEs reported from the ICAP patient population in the sponsor's safety database up to June 30, 2016, were retrieved and included in the analysis.
Retrospective chart review study design
A retrospective chart review study was conducted in a subset of US oncology practices that treated 1 or more patients with gefitinib as part of the ICAP (coordinating investigators for the ICAP retrospective chart review are listed in the online Appendix). All IRB approvals were obtained before data collection. The eligibility period was the same as the enrollment period for the ICAP (June 2011 to January 2013). Patients aged 18 years were eligible if they had a confirmed diagnosis of cancer, had received at least 1 dose of gefitinib as part of the ICAP during the eligibility period, and had not withdrawn their consent from the ICAP; although it was not an eligibility criterion, most patients had previously been benefitting from gefitinib for at least 3 years at ICAP entry because of the timing of events affecting access to gefitinib as outlined above. Data were collected by local center staff from the patient medical charts and recorded onto paper-based case-report forms between May 2015 and August 2016. Data from the paper case-report forms were entered by double data entry into the study database by the studycoordinating center. The study involved no intervention and thus did not affect patient treatment. No patientidentification information was collected. The intent was to include as many patients enrolled into the ICAP as feasibly possible (of 191 patients from 137 sites), and enrollment was contingent on investigator interest in chart review participation. An overview of the study cohort enrollment is presented in Supporting Figure 1 .
Data Collection
Center staff extracted de-identified data from patient medical charts for patient demographics, medical history, and disease characteristics, history of treatment (systemic therapies before gefitinib, gefitinib treatment patterns, first Original Article treatment after ICAP discontinuation, surgical procedures, and radiotherapy after gefitinib initiation), response to treatment (first treatment response after gefitinib initiation, most recent response pre-ICAP initiation, and treatment response during ICAP), and survival status. In addition to the SAEs reported for all patients in the overall ICAP populations, other safety information and adverse events (AEs) were extracted during ICAP. The quality of study data was assured through remote monitoring of study sites, provision of appropriate training for study personnel, and the use of data-management procedures.
Statistical Analyses
For the analyses of the overall cohort and the subset included in the retrospective chart review, there was no intention to test any formal, prespecified hypotheses. Results of the safety database analysis are summarized descriptively, including the numbers and percentages of the ICAP patients who reported SAEs, causality of the SAEs in relation to gefitinib, SAEs leading to discontinuation, and SAEs with the outcome of death. Causes of death other than SAEs also are summarized. For continuous variables, mean, standard deviation, median, quartiles, and minimum/maximum values are provided; and, for categorical variables, numbers and percentages for each category are provided. Time-to-event analyses were assessed using Kaplan-Meier estimates.
RESULTS
Overall ICAP Population
In total, 191 patients received gefitinib through the ICAP program. Limited demographic information is available for this cohort because of the nature of the access program. Seventy-five of the 191 patients (39%) who entered ICAP remained on active treatment as of September 2016. Those who discontinued (n 5 116) did so because of disease progression (n 5 42; 36%), death (n 5 39; 34%), AEs (n 5 15; 13%), or other reasons, such as patient or physician decisions (n 5 20; 17%).
Sponsor Safety Database Analysis
In total, 162 SAEs were reported from 64 (34%) of the 191 ICAP patients as of June 30, 2016, including 40 women (62.5%), with mean age of 73 years (age range, 23-98 years) at the time of the SAE reporting. The majority of the reported SAEs (152; 94%) were considered to be unrelated to gefitinib treatment and consistent with underlying disease conditions or comorbidities. Three patients (1.6%) who had been receiving gefitinib for 6, 7, and 11 years, respectively, experienced SAEs that were considered by their investigators to be possibly related to gefitinib treatment (Table 1 ). Two of those 3 patients discontinued treatment because of their reported SAEs. The third patient remained on gefitinib after the onset of the SAEs (lung infection and chronic obstructive pulmonary disease exacerbations) and died of exacerbation of chronic obstructive pulmonary disease 11 weeks later.
Chart Review Cohort
Patient population
Among the subpopulation of patients who underwent chart review (n 5 79), 55 patients (70%) were women, 46 (58%) were former smokers, 24 (30%) were neversmokers, and 6 (8%) were current smokers (Table 2) . Adenocarcinoma was diagnosed in 44 patients (56%), and squamous carcinoma was diagnosed in 10 patients (13%). The remaining patients had other or mixed histologies, or their histology was unknown. Seventeen patients (22%) underwent EGFR mutational status testing; and, of these, 10 patients (59%) reportedly had tumors that were positive for EGFR mutation (Table 3) . Of the 7 patients who had EGFR-mutation-negative tumors, 6 were receiving treatment for 2.7 years and 1 was receiving treatment for >5 years. Details about the type of mutation testing conducted were not abstracted.
Gefitinib treatment
Most of the 79 patients (54%) received gefitinib therapy as first-line treatment for advanced NSCLC, whereas 27% received gefitinib as second-line therapy, and 19% received it as a later line of therapy (Table 2 ). For patients in whom the initial dose of gefitinib was known (n 5 67), the starting dose was 250 mg daily. Before ICAP initiation, patients received gefitinib predominantly as monotherapy (84%). The median treatment duration before ICAP was 7.8 years (range, 5.4-10.9 years), with an additional 3.5 years (range, 0.04-4.7 years) during the ICAP chart review period. The total median treatment duration from the first-ever receipt of gefitinib was 11.1 years (range, 6.5-15.1 years).
Adverse events
Forty-eight of 79 patients (61%) experienced AEs, and 21 patients (27%) had SAEs. Gefitinib-related AEs were observed in 16 patients (20%), and 1 patient (1%) had a gefitinib-related SAE. The gefitinib-related AEs were mostly gastrointestinal symptoms with diarrhea (in 7 patients; 9%), and only 1 patient (1%) had a grade 3 reaction. Skin rash occurred in 5 patients (6%), and no patients had grade 3 rash (Table 4) . None of the more well-known late toxicities observed with traditional chemotherapy were observed, such as cardiotoxicity, central nervous system toxicity, or the development of secondary cancers. 
Abbreviations: ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene homolog; L858R, leucine-to-arginine substitution at position 858. Dose modifications because of gefitinib-related AEs occurred in 4 patients (5%) before ICAP, and dose interruptions because of gefitinib-related AEs occurred in 13 patients (17%) before ICAP and in 1 patient during ICAP. Discontinuation because of gefitinib-related AEs occurred in 4 patients (5%) during ICAP, whereas discontinuation because of progressive disease was reported in 11 patients (29%). Discontinuations because of death (unrelated to treatment) were observed in 11 patients (29%); 5 discontinuations were because of non-SAEs, and 7 were from other causes.
Survival
In total, 56 patients (71%) were living at the time of the chart review. The overall survival (OS) curve from the first-ever initiation of gefitinib is illustrated in Figure 1 . The 10-year survival rate from first-ever initiation of gefitinib was 86%, and the 15-year survival rate was 59%. The OS curve from the first-ever cancer diagnosis is illustrated in Figure 2 . There were 23 deaths, of which none were related to gefitinib-related SAEs; 9 were from lung cancer, 5 were from other nongefitinib-related causes, 5 were from SAEs not related to gefitinib, and 4 were from unknown causes.
DISCUSSION
This is the first study to evaluate and report on the longterm use of gefitinib. We observed that long-term use of gefitinib, with a median length of treatment of 11.1 years (7.8 years before and 3.5 years after ICAP), was well tolerated, with only 1% of patients experiencing severe drugrelated toxicity. The way history unfolded in the case of gefitinib, with a period of regulatory approval but subsequent limitation of access, allowed for the ICAP program to serve as a complete registry of all US patients who were receiving gefitinib from 2011 to 2015. This was a unique opportunity for real-world assessment of an oncology therapeutic agent. In the initial gefitinib clinical trials, the majority of toxicities occurred early in the course of therapy, at about the time steady-state serum levels were reached. These were most frequently cutaneous or gastrointestinal in nature and led to dose reductions in a minority (<1%) of patients. 17, 18 It has not been firmly established whether gefitinib dose reductions influenced the outcome and duration of therapy; however, in a study that examined this issue, outcomes appeared clinically equivalent between those who received the standard regimen (250 mg daily) and those who required a dose reduction because of toxicity. 19 Of note, an analysis of afatinib, a newer, irreversible EGFR TKI used as first-line therapy in patients with EGFR-mutation-positive NSCLC, demonstrated that dose reduction to manage drug-related side effects had no adverse effect on progression-free survival. 20 Similarly, the published literature on gefitinib suggests that the median duration of response is about 10 months, but a subset of patients is on the "tail of the curve," with durable responses lasting for years. 9, 16 However, there is scant information about late toxicities and long-term tolerance. It is known that chemotherapy can be associated with cardiotoxicity and central nervous system toxicity, and the eventual development of secondary malignancies is reported in some patients; however, none of these issues were observed in this study of gefitinib. These AEs can have long-term consequences, but few studies have investigated the effects of such late toxicities on factors like patient quality of life, and no trials of this design could be identified within the literature about NSCLC. A study of 921 patients who had either breast or colon cancer demonstrated that chemotherapy was associated with lower health-related quality of life compared with hormone therapy at 5-year to 8-year follow-up. 21 In a study of 245 breast cancer survivors, from 9.4 to 16.5 years postdiagnosis, univariate analysis demonstrated a statistically significant difference in health-related quality of life between those who had received low-dose chemotherapy and those who had received standard-dose or high-dose chemotherapy; however, multivariate analysis indicated that other factors, such as older age, the presence of comorbidities, lower vitality, and increased menopausal symptoms, had greater influence. 22 A study of 163 breast cancer survivors who were followed for 5 to 13 years indicated that initial chemotherapy predicted greater financial problems and greater worry about appearance at followup. 23 In a trial of 32 men who had testicular cancer cured with orchidectomy plus cisplatin-based and doxorubicinbased chemotherapy and were followed for 13 years, although various long-term toxicities were reported (eg, peripheral neuropathy, Raynaud phenomenon, hearing reduction), all participants denied any limitations on their social or working life. 24 Similar studies are needed in NSCLC now that the number of long-term survivors is increasing because of more effective therapeutic options.
Although this is the first study reporting on longterm tolerance to gefitinib, comparable studies are currently ongoing in Asia and Europe based on similar patient populations. The comparison of those studies eventually may uncover racial differences, if any, in longterm tolerance of gefitinib.
We must note that the ICAP study is limited by selection bias of the patient population. To qualify for enrollment, patients had to have been benefiting from gefitinib for at least 3 years, because the timing of ICAP started 3 years after gefitinib was made unavailable for new prescription starts in the United States. In addition, the study population in the retrospective chart review was relatively small (n 5 79), and the data collected were limited (patient demographics, medical history and disease characteristics, treatment regimen, response, survival, and safety). Finally, when the patients in the ICAP were diagnosed with lung cancer, genetic testing was not widely available. Indeed, for some patients, diagnosis predated the discovery of EGFR mutations. Consequently, the majority of patients did not ever have tumor genotyping performed. For the minority of patients who did receive testing (n 5 17), almost 60% had EGFR-mutation-positive tumors. Among the 10 patients with EGFR-mutation-positive tumors, none had squamous cell carcinoma. It is important to keep in mind that the testing methods at the time likely were outdated compared with today's standards and potentially included a variety of techniques, coverages, and sensitivities. Because of the extremely long benefit of gefitinib observed in this select population, we assume that, based on current knowledge, the majority of tumors were positive for EGFR mutation.
Although it is well known that driver EGFR mutations in exons 19 and 21 predict favorable outcomes with EGFR TKIs, the effect of the passenger mutation landscape on modulating treatment outcome is unknown. Other biomarkers may influence treatment results in a negative or positive fashion, such as tumor protein 53 (p53) mutation, epithelial-mesenchymal transition (EMT), and mitogen-activated protein kinase 1 (MAPK1). [25] [26] [27] [28] [29] It is important to identify genomic markers that predict not only who may respond to EGFR TKI therapy but also who may not respond to avoid unnecessary side effects and costs in those with no expected clinical benefit. To learn more about the molecular profile of the long-term survivors, the investigators have planned to retrieve tumor specimens from patients
Original Article who did not undergo mutation analysis to analyze their genomic profile. However, the age and availability of these tissue samples may challenge these analyses.
Conclusion
In conclusion, a high percentage of patients in the ICAP program were long-term gefitinib responders, with a 15-year survival rate of almost 60%, although this subset of patients may not be representative of the general population of those who survive 3 years. In these patients, gefitinib was well tolerated with a median treatment duration of more than 10 years. Clinical and genetic features associated with such long-term benefit warrant further studies.
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